|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Trade receivables, net | ||||||||||||||||||||
| Partnership receivables | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Clinical trial retainers | ||||||||||||||||||||
| Other prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued clinical trial costs and contract research | ||||||||||||||||||||
| Accrued clinical trial costs and contract manufacturing | ||||||||||||||||||||
| Accrued compensation and benefits | ||||||||||||||||||||
| Other accrued liabilities | ||||||||||||||||||||
| Operating lease liability | ||||||||||||||||||||
| Less loans payable current, net of discount | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Deferred research and development reimbursements | ||||||||||||||||||||
| PIPE Warrant liability | ||||||||||||||||||||
| Other liabilities (Note 6) | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Loans payable, net of discount | ||||||||||||||||||||
| Deferred revenue, non-current | ||||||||||||||||||||
| PIPE Warrant liability (Note 7) | ||||||||||||||||||||
| Operating lease liability, non-current | ||||||||||||||||||||
| Other liabilities, non-current (Note 6) | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock, $0.001 par value: 5,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at each of September 30, 2022 and December 31, 2021 | ||||||||||||||||||||
| Common stock, $0.001 par value: 80,000 shares authorized at September 30, 2022 and 50,000 at December 31, 2021; 34,621 shares issued and outstanding at September 30, 2022 and 34,475 at December 31, 2021 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
